The parties agree that Seller need not further object to any specific terms and conditions set by Buyer; such failure to object to Buyer’s specific terms and conditions is not an acceptance of any such terms and conditions. Danach genehmigt der Käufer die Rechnung automatisch. 7.5 If Buyer has not paid the purchase price within the period defined in clause 7.1 above, Seller may set Buyer a deadline of fifteen (15) days for payment. NO PUBLICITY Buyer shall not use Seller’s name or trademarks in any advertisements, product descriptions, packaging materials, websites, or any other promotional materials, except with the prior written consent of Seller.

The control points are generally set to control known sources of variance. Key performance indicators and goals are set for each business 8. Goals are set by facility and function for reduction in complaints.

Patterson President and Chief Executive Officer PolyOne Corporation Page 5 PolyOne Leadership Name Title Name Title Stephen D. Patterson President and Chief Executive Officer PolyOne Corporation Page 27 Well Positioned for Revenue Growth Addressable Market by Platform $540 $215 $120 $40 $260 $525 ($ millions) Design/Service Sustainable Solutions Surface Modification Lightweighting Thermal Control Flame Retardancy $1.0 - $2.0 Billion of revenue generated from new products in 5 years Gross margin on new products exceed current gross margin by at least 10 percentage points World class vitality index of ≥ 35% 2018 PolyOne Corporation Page 28 Megatrends Aligned with Key End Markets Decreasing Dependence on Fossil Fuels Protecting the Environment Improving Health and Wellness Megatrend End Markets Globalizing and Localizing Health & Wellness Transportation Packaging Consumer PolyOne Corporation Page 29 2006 2013 Revenue ($ millions) Health and Wellness Evolution General purpose tubing TPE applications from GLS Specialty tubing Ergonomic enhancements Pre-certified biocompatible colorants Highly sophisticated catheter and drug delivery components Chemical and heat sterilizable materials Authentication and protection technologies Addressing wellness, prevention, diagnostic and therapy changes in healthcare setting Healthcare packaging solutions 2006 2015 & Beyond $416 $105 PolyOne Corporation Page 30 Transportation Evolution General purpose formulations (bumpers, roof racks) Long fiber for lightweighting Thermal management for LED lighting Thermoset composite pultrusions Conductive polymers for EMI shielding Formulations for aerospace interiors Thermoplastic composites High temperature formulations for aerospace Expand 3D printing capabilities 2006 2015 & Beyond 2006 2013 Revenue ($ millions) $709 $315 PolyOne Corporation Page 31 Packaging Evolution Masterbatch colors and PVC packaging materials TPEs to enhance brand appeal and consumer functionality Liquid color and additive technologies to extend shelf life, preserve taste and differentiate brands Leveraging color, additives and sheet technology for healthcare and consumer packaging solutions 2006 2015 & Beyond 2006 2013 Revenue ($ millions) $612 $260 PolyOne Corporation Page 32 Consumer Evolution Commodity plastic and masterbatch color solutions Engineered materials to enhance customer appeal through visual and performance improvements Formulated metal- to-polymer conversion to enhance performance and reduce manufacturing costs Biopolymers & composite materials leveraging unique color technology to build brand identity 2006 2015 & Beyond 2006 2013 Revenue ($ millions) $394 $228 PolyOne Corporation Page 33 Interactive Display Introduction PolyOne Corporation Page 34 Interactive Displays INNOVATION DISCUSSION LEADER TECHNOLOGIES MARKETS Polycast™ Bullet Resistant Sheet Aerospace GlasArmor™ Ballistic Resistant Panels Security reFlex™ Bio-Based Plasticizer Solutions Wilflex™ Oasis Hydrate InVisiO℠ Color Inspiration Forecast In-Store Audits OnColor™ Portfolio Light Weighting Thermal Management Corrosion Resistance Design Flexibility Sustainability Global Supply Chain Ergonomics and Aesthetics Consumer Appeal 9) Consumer Electronics Solutions Walter Ripple General Manager GLS Personal Electronics Wearable Electronics Hand Held Devices Portable Audio 7) Metal Replacement Technology Kurt Schuering Vice President Global Key Account Management Aerospace Sporting and Shooting 8) Medical Device Solutions Dr.

Setting and periodically reviewing environmental objectives and targets assures excellence in environmental leadership. Avient strives to be the industry leader in safety and health by setting aggressive goals, measuring performance, and making necessary adjustments.  Setting goals and objectives that drive continual improvement and check effectiveness of risk reduction measures in product safety and stewardship

Setting and periodically reviewing environmental objectives and targets assures excellence in environmental leadership. Avient will be the leader in safety and health by setting aggressive goals, measuring performance, and making adjustments when necessary.  Setting goals and objectives that drive continual improvement and check effectiveness of risk reduction measures in product safety and stewardship

Microsoft PowerPoint - PolyOne Investor Presentation 5.4.20_v8 P E O P LE P RO D U CT S P LA N E T P E RF O R MAN C E JVs Performance Products & Solutions Distribution Specialty To be the world’s premier provider of specialized polymer materials, services and solutions To be the world’s premier provider of specialized polymer materials, services and sustainable solutions 2016 2017 2018 2019 Lightweighting Reduced Material Requirements Improved Recyclability Renewable Energy Applications Eco-conscious Bio-derived Content Reduced Energy Use VOC Reduction $275M $325M $355M $410M 14% Total Annual Growth 9% Organic Annual Growth PolyOne Corporation 33 Adjusted EPS attributable to PolyOne common shareholders is calculated as follows: 2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016** 2017** 2018 2018*** Q1 2019*** 2019 Q1 2020 Net income from continuing operations attributable to PolyOne common shareholders Joint venture equity earnings, after tax Special items, before tax(1) Special items, tax adjustments(1) Adjusted net income from continuing operations attributable to PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 $ 161.1 $ 87.7 $ 22.4 $ 75.5 $ 33.1 (19.0) (14.7) (3.7) — — — — — — — — — — — (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 59.5 58.7 12.2 61.7 9.6 (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) (25.3) (25.1) (1.2) (5.9) (1.0) $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 $ 195.3 $ 121.3 $ 33.4 $ 131.3 $ 41.7 Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 80.4 80.4 78.2 77.7 86.7 Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 $ 2.43 $ 1.51 $ 0.43 $ 1.69 $ 0.48 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation. ** Pro forma for sale of Designed Structures and Solutions segment (DSS). *** Pro forma for sale of Performance Products and Solutions segment (PP&S).

Microsoft PowerPoint - PolyOne Investor Presentation 5.4.20_v8 P E O P LE P RO D U CT S P LA N E T P E RF O R MAN C E JVs Performance Products & Solutions Distribution Specialty To be the world’s premier provider of specialized polymer materials, services and solutions To be the world’s premier provider of specialized polymer materials, services and sustainable solutions 2016 2017 2018 2019 Lightweighting Reduced Material Requirements Improved Recyclability Renewable Energy Applications Eco-conscious Bio-derived Content Reduced Energy Use VOC Reduction $275M $325M $355M $410M 14% Total Annual Growth 9% Organic Annual Growth PolyOne Corporation 33 Adjusted EPS attributable to PolyOne common shareholders is calculated as follows: 2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016** 2017** 2018 2018*** Q1 2019*** 2019 Q1 2020 Net income from continuing operations attributable to PolyOne common shareholders Joint venture equity earnings, after tax Special items, before tax(1) Special items, tax adjustments(1) Adjusted net income from continuing operations attributable to PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 $ 161.1 $ 87.7 $ 22.4 $ 75.5 $ 33.1 (19.0) (14.7) (3.7) — — — — — — — — — — — (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 59.5 58.7 12.2 61.7 9.6 (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) (25.3) (25.1) (1.2) (5.9) (1.0) $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 $ 195.3 $ 121.3 $ 33.4 $ 131.3 $ 41.7 Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 80.4 80.4 78.2 77.7 86.7 Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 $ 2.43 $ 1.51 $ 0.43 $ 1.69 $ 0.48 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation. ** Pro forma for sale of Designed Structures and Solutions segment (DSS). *** Pro forma for sale of Performance Products and Solutions segment (PP&S).

KEY CHARACTERISTICS • Manufactured under change control principles beyond CAS number (similar level as MEVOPUR concentrates), reducing risk of change • Free from animal-derived substances and phthalates • Suitable for blown film, injection molding, blow molding and extrusion REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 - USP chapters , including Class VI, a requirement for ophthalmic and nasal drugs - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities - USP and USP light transmission • Registered Drug Master File (Type III) • Food contact compliance established with FDA/EU* APPLICATION BULLETIN CARRIER MATERIAL PIGMENT CONTENT/TYPE LIGHT FASTNESS THERMAL STABILITY PRODUCT CODE HDPE 50% TiO2 8 300°C PH00075525 LLDPE 60% TiO2 8 300°C PL00075542 LLDPE 70% TiO2 8 300°C PL00075545 PP 50% TiO2 8 300°C PP00075717 Healthcare use limitations apply—see below.

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Non-phthalate and formulated without animal-derived substances • Color can be combined with additives to enhance performance and protection REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Device Master File • Food contact established with FDA/EU* NOMINAL OUTSIDE DIAMETER OF NEEDLE (MM) COLOR DESCRIPTION RAL PANTONE TRANSPARENT PRODUCT CODE OPAQUE PRODUCT CODE 0.4 Medium Grey 7035 423 C PP7M665125 PP7M665127 0.45 Brown 8017 7588 C PP8M665294 PP8M665296 0.5 Orange 2003 173 C PP2M665298 PP2M665300 0.55 Medium Purple 4005 7676 C PP4M665290 PP4M665292 0.6 Deep Blue 5010 288 C PP5M665894 PP5M665896 0.7 Black 9005 Black C PP9M664950 PP9M664952 0.8 Deep Green 6001 7483 C PP6M665687 PP6M665689 0.9 Yellow 1021 115 C PP1M665211 PP1M665213 1.1 Cream 1015 7401 C PP0M665290 PP0M665292 1.2 Pink 3015 502 C PE3M665725 PP3M665727 Healthcare use limitations apply—see below.

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified manufacturing sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Non-phthalate and formulated without animal- derived substances • Standard concentrates in a PE carrier and on request in PP • Pre-colored formulations can be supplied in specific resins selected for the application REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) • Food contact established with FDA/EU* APPLICATION BULLETIN DRUG TYPE COLOR DESCRIPTION PANTONE REFERENCE AVIENT PRODUCT CODE PE BASED Adrenergic agonist combinations Light Green 373 C PE6M176349 Adrenergic agonists Purple 2583 C PE4M176057 Anti-infectives Tan 467 C PE8M176130 Anti-inflammatory, nonsteroidal Grey Cool Grey 4 C PE7M176184 steroids Pink 197 C PE3M176237 Anti-inflammatory, immunomodulators Olive Green 5763 C On request Beta-blockers Yellow Yellow C PE1M176160 Beta-blocker combinations Dark Blue 281 C PE5M176272 Carbonic anhydrase inhibitors Orange 1585 C PE2M176089 Cytotoxic Black 6 C PL9M176008 Miotics Dark Green 348 C PE6M176267 Mydriatics and cycloplegics Red 1797 C PE3M176236 Prostaglandin analogues Turquoise 326 C PE5M176273 Healthcare use limitations apply—see below.